Glaucoma and Dry Eye

Dry eye disease and glaucoma often occur together, especially because some glaucoma eye drops can affect the tear film and make symptoms like burning, irritation, watering, or fluctuating vision worse. Early diagnosis and treatment of both conditions can improve comfort and help protect long-term vision.

Glaucoma and dry eye disease occur together more often than chance alone explains. If your eyes burn, sting, or feel gritty while you are on glaucoma drops, you are not imagining it. This combination is common, clinically important, and often undertreated.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


How Common Is Glaucoma and Dry Eye Overlap?

Studies consistently show that 40 to 60 percent of glaucoma patients meet diagnostic criteria for dry eye disease. The reverse is also true: people with moderate to severe dry eye carry a higher risk of developing glaucoma-related damage. These are not coincidental companions. They share biological mechanisms, and each condition can quietly worsen the other.


Why Does Dry Eye Develop in Glaucoma Patients?

The preservative problem

Most glaucoma eye drops contain benzalkonium chloride (BAK) as a preservative. BAK is effective at keeping the bottle sterile, but it is toxic to the cells of the ocular surface. It disrupts the tear film, damages goblet cells (the cells that produce the mucin layer of your tears), and triggers chronic inflammation.

Patients who use two or three glaucoma drops daily — each containing BAK — are exposing their eyes to this preservative four, six, or more times every day. Over months and years, the cumulative damage is significant. The conjunctiva becomes inflamed, the cornea loses its smooth optical surface, and the eyes feel perpetually uncomfortable.

This is not a rare side effect. It is an expected biological consequence of long-term BAK exposure, and it is one of the most underrecognised sources of glaucoma-related suffering.

Pre-existing risk

Dry eye disease is more common in the same demographic groups that develop glaucoma: older adults, women after menopause, and people with autoimmune conditions. Many patients arrive at a glaucoma diagnosis already carrying a degree of ocular surface disease. Adding BAK-containing drops to a compromised surface accelerates the damage.

Reduced blink rate

Glaucoma patients and patients with dry eye often share a common modern risk factor: prolonged screen use. Reduced blink rate during screen time is one of the fastest-growing contributors to evaporative dry eye, and it worsens the tolerance to topical medications.


Why Does This Overlap Matter Clinically?

Medication adherence

Dry eye makes glaucoma drops uncomfortable. Burning, stinging, and a sense of grittiness after instillation are among the most common reasons patients quietly reduce their drop frequency or stop altogether. This is rational behaviour in response to pain — but the result is uncontrolled intraocular pressure and silent glaucoma progression.

Treating dry eye is not a cosmetic afterthought. It is a strategy for protecting adherence, which protects the optic nerve.

Diagnostic accuracy

Dry eye causes variable intraocular pressure readings. Epithelial irregularity from a damaged ocular surface can affect tonometry (pressure measurement) and cause artificially high or variable readings. This creates noise in the data your glaucoma specialist depends on.

Similarly, a poor ocular surface causes artefacts in OCT scans and visual field tests. Blurring from unstable tear film produces dips and losses in visual field testing that mimic glaucoma progression. Distinguishing true nerve damage from tear-film artefact requires a clinician who is looking for both.

Quality of life

Glaucoma itself does not hurt and often produces no symptoms until late. But the treatment — the drops — can make patients miserable. Chronic ocular surface pain, light sensitivity, and fluctuating vision are quality-of-life burdens that patients often accept as inevitable. They are not inevitable.


How Do We Assess This in the Clinic?

A comprehensive evaluation for a glaucoma patient with ocular surface complaints includes:

  • Tear film assessment: Tear breakup time (TBUT) measures how quickly your tear film breaks apart after a blink. In dry eye, this is shortened.
  • Ocular surface staining: Fluorescein and lissamine green dyes reveal damaged cells on the cornea and conjunctiva.
  • Meibomian gland evaluation: Most dry eye in glaucoma patients is evaporative, caused by dysfunction of the oil-producing meibomian glands at the lid margins.
  • Symptom questionnaires: Validated tools like OSDI (Ocular Surface Disease Index) capture the patient experience beyond what the slit lamp shows.
  • Review of the current drop regimen: How many drops, which preservatives, how many times daily.

What Are the Management Options?

Switching to preservative-free formulations

This is often the single most impactful intervention. Preservative-free glaucoma drops deliver the same intraocular pressure-lowering effect without the chronic ocular surface toxicity. Multiple classes of glaucoma medication are now available in preservative-free formats: prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors, and fixed-dose combinations.

The transition requires some planning — not all formulations are available in preservative-free versions in every market, and cost is a factor — but for patients with documented ocular surface disease, this is a clinically justified switch that most guidelines now support.

Fixed-dose combination drops

Instead of using two bottles separately (each with its own preservative load), a fixed-dose combination delivers two active ingredients in one drop. This halves the number of preservative exposures per day. For patients who genuinely need two active agents, this is a practical step even before moving to preservative-free options.

Treating the dry eye directly

Ocular surface disease responds to targeted treatment. The approach depends on the type and severity:

  • Artificial tears: Lubricating drops, preferably preservative-free, used consistently throughout the day. These dilute residual BAK, stabilise the tear film, and reduce surface friction.
  • Warm compresses and lid hygiene: For meibomian gland dysfunction, daily warm compress application followed by gentle lid massage improves the quality of the oily tear layer.
  • Omega-3 supplementation: Good evidence supports dietary omega-3 fatty acids for meibomian gland function and tear quality.
  • Anti-inflammatory therapy: Topical cyclosporine (Restasis, Ikervis) or lifitegrast addresses the inflammatory cycle that perpetuates chronic dry eye. In patients with significant ocular surface inflammation, this can be transformative.
  • Punctal plugs: Small silicone plugs inserted into the tear drainage points slow the drainage of natural tears, keeping the eye surface better hydrated.

Laser and surgical IOP control

For some patients, reducing or eliminating the need for topical drops altogether is the right goal. Selective laser trabeculoplasty (SLT) can lower IOP without any drops. For more advanced glaucoma, surgical options including minimally invasive glaucoma surgery (MIGS) and trabeculectomy may reduce drop burden significantly. When a patient’s ocular surface is severely compromised by long-term drop use, a surgical discussion is worth having.


A Note on Sequence and Timing

When a patient presents with both conditions, the sequence of assessment matters. Dry eye can artificially distort IOP readings and OCT quality. I prefer to stabilise the ocular surface first — or at least treat both simultaneously — so that subsequent glaucoma monitoring data is reliable. A visual field test performed through an unstable tear film is not a trustworthy test.


What Should You Tell Your Doctor?

If you are being treated for glaucoma and your eyes feel uncomfortable, please say so explicitly. Many patients assume irritation is part of the package and do not raise it. Your doctor needs to know:

  • Which symptoms bother you most (burning, grittiness, blurred vision, light sensitivity)
  • Whether symptoms are worse at certain times of day or after drop instillation
  • Whether you have ever reduced or skipped your drops because of discomfort
  • Whether you use a screen for extended hours daily

This information changes the clinical approach. It does not make you a difficult patient — it makes your care more precise.


Frequently Asked Questions

Can glaucoma drops cause dry eye?

Yes. Most glaucoma drops contain benzalkonium chloride, a preservative that damages the ocular surface over time. Long-term exposure causes inflammation, goblet cell loss, and dry eye disease. Switching to preservative-free formulations often brings significant relief.

Do I have to choose between treating my glaucoma and treating my dry eye?

No. Both conditions can and should be managed simultaneously. In many cases, treating dry eye actively improves the tolerability of glaucoma drops and supports adherence to treatment, which protects the optic nerve.

Are preservative-free glaucoma drops as effective as regular drops?

Yes. The active ingredient is the same. The preservative is only there to keep the bottle sterile between uses. Preservative-free formulations use single-dose units instead, delivering the same intraocular pressure-lowering effect without the surface toxicity.

Can dry eye affect my glaucoma test results?

Yes. An unstable tear film causes variable IOP readings and artefacts in visual field and OCT testing. This is one reason a thorough ocular surface assessment is part of comprehensive glaucoma care.

I use three different glaucoma drops. Is that a problem for my eyes?

Three separate bottles often means three doses of BAK per application. This is a significant preservative load. A conversation about fixed-dose combinations or preservative-free alternatives is worth having with your glaucoma specialist.

Is laser treatment an option if my eyes cannot tolerate drops?

Yes. Selective laser trabeculoplasty (SLT) can lower IOP and reduce dependence on drops. For patients whose ocular surface disease is severe and driven by drop toxicity, reducing the drop burden through laser or surgery is a clinically sound strategy.


Internal Linking Architecture Statement

This page is part of the Glaucoma Hub hub. Read about our full approach to glaucoma diagnosis, monitoring, and treatment. Please also read our Dry Eye Hub. Here’s another heartening patient story: Tired of glaucoma eyedrops.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Read More

Basics of Dry Eye, Dry Eye Second Opinion, Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often? Menopause and Dry Eye

Dry Eyes: Natural Remedies, Dry Eyes: Tips to Soothe Sore Eyes

Why Dry Eye Is Worse in Air Conditioning and on Flights

Screen Fatigue, Why Vision Becomes Blurred After Reading or Screen Use,

Why Your Eyes Water Constantly, Omega-3 and Dry Eye, Why Are Your Dry Eye Drops Not Working

Glaucoma Eye Drops: The Complete Guide, Laser or Eye Drops for Glaucoma

Managing Glaucoma Eye Drop Side Effects, Which Is the Best Eyedrop for Glaucoma?

Why Do I Need So Many Glaucoma Eye Drops?

Dry Eye Is Not Just Dryness: Managing It as a Chronic Condition

Dry eye disease is a chronic condition caused by an unstable or insufficient tear film. It does not go away with occasional lubricating drops. Left unmanaged, it causes progressive surface damage, worsening discomfort, and, in some cases, permanent corneal scarring. Long-term management, not short-term relief, is the correct approach, says Dr Shibal Bhartiya.

Dry eye is one of the most common eye conditions seen in clinical practice. Most patients manage it with over-the-counter drops and expect it to resolve. It rarely does.

Dry eye disease is a multifactorial condition of the ocular surface. The tear film is complex. When it breaks down, the result is inflammation, epithelial damage, and a cycle that perpetuates itself without targeted treatment.

Understanding dry eye as a chronic disease changes how patients manage it, and how much vision and comfort they can preserve over time.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.

What Is Dry Eye Disease?

Dry eye disease (DED) is defined by the TFOS DEWS II report as a multifactorial disease of the ocular surface. It involves loss of tear film stability and is accompanied by symptoms and signs of varying severity.

The tear film has three layers: a mucin layer anchoring tears to the eye surface, an aqueous (watery) layer providing nutrients and oxygen, and a lipid (or oil) layer produced by the meibomian glands that prevents evaporation. A problem in any one layer causes disease.

Two Main Types of Dry Eye

Aqueous Deficient Dry Eye

This type involves insufficient tear production. The lacrimal gland does not produce enough aqueous fluid. It is common in post-menopausal women, patients with Sjogren’s syndrome, and those on antihistamines, antidepressants, or blood pressure medications.

Evaporative Dry Eye

This is the more common type, accounting for roughly 85 percent of all dry eye cases. Meibomian gland dysfunction (MGD) is the primary cause. Blocked or abnormal meibomian glands fail to secrete a healthy lipid layer, and tears evaporate too quickly.

Many patients have both types simultaneously. Treatment must address the dominant mechanism.

FeatureAqueous Deficient DEDEvaporative DED
Primary causeReduced lacrimal gland outputMeibomian gland dysfunction
Proportion of casesApproximately 15%Approximately 85%
Key risk factorsSjogren’s, medications, ageScreen use, blepharitis, rosacea
Tear break-up timeReducedVery short (under 5 seconds)
Treatment focusTear supplementationLid hygiene, heat, omega-3
Inflammation presentOften yesYes, secondary

Why Dry Eye Becomes Chronic

The tear film and ocular surface exist in a feedback loop. When the tear film is unstable, the surface desiccates. This triggers inflammation. Inflammation damages goblet cells and lacrimal tissue. Damaged tissue produces less stable tears. The cycle continues.

Without breaking this cycle, not just lubricating the surface, dry eye worsens over months and years. This is why patients who only use drops often find their symptoms returning or intensifying.

Chronic untreated dry eye can cause corneal epithelial breakdown, punctate keratitis, subepithelial scarring, and, in severe cases, corneal ulcers. These are not trivial outcomes.

Risk Factors That Drive Progression

  • Screen use of more than four hours daily reduces blink rate and increases evaporation.
  • Contact lens wear disrupts the tear film and accelerates meibomian gland dropout.
  • Hormonal changes — especially menopause — reduce lacrimal and meibomian secretions.
  • Systemic medications including antihistamines, SSRIs, diuretics, and isotretinoin reduce tear production.
  • Autoimmune conditions such as rheumatoid arthritis, lupus, and thyroid disease affect the lacrimal gland.
  • Rosacea is a strong risk factor for meibomian gland dysfunction and is frequently undiagnosed.
  • Air conditioning, low humidity, and air travel accelerate tear evaporation.
  • Prior LASIK or refractive surgery causes corneal nerve damage and temporarily reduces reflex tearing.

How Dry Eye Is Diagnosed

Diagnosis requires more than a symptom questionnaire. A structured assessment includes the OSDI (Ocular Surface Disease Index) score, tear break-up time (TBUT), Schirmer’s test, corneal and conjunctival staining with fluorescein and lissamine green, and meibomian gland evaluation.

Meibography — infrared imaging of the meibomian glands — shows the degree of gland dropout and guides treatment intensity. Patients with significant gland loss need early and aggressive intervention to preserve remaining function.

Tear osmolarity testing measures the salt concentration of tears. Elevated osmolarity confirms tear film instability and is useful for monitoring treatment response objectively.

Diagnostic TestWhat It MeasuresClinical Significance
TBUT (tear break-up time)Tear film stabilityUnder 10 seconds is abnormal
Schirmer’s testAqueous tear productionUnder 10 mm in 5 min is reduced
Corneal fluorescein stainingEpithelial surface damageConfirms active disease severity
MeibographyMeibomian gland structure and dropoutGuides long-term prognosis
Tear osmolarityTear salt concentrationOver 308 mOsm/L confirms DED
OSDI scoreSymptom burdenTracks treatment response over time

If screen-related eye pain is affecting your work or daily life, a full assessment takes under an hour. Dr Shibal Bhartiya — dry eye specialist and glaucoma specialist in Gurgaon — will identify whether this is screen strain or something that needs treatment. 📞 +91 88826 38735 | www.drshibalbhartiya.com


This article is part of the Dry Eye Hub. Please also read Basics of Dry Eye, Dry Eye Second Opinion and Dry Eye: A Chronic Disease. Why Vision Becomes Blurred After Reading or Screen Use, and Why Are Your Dry Eye Drops Not Working may also help you understand your problem better.

You may also want to read this article written by Dr Bhartiya for NDTV online. And listen to her talk about dry eyes here.


Treatment: A Layered Approach

Dry eye treatment is not one-size-fits-all. It is matched to disease type, severity, and the dominant mechanism driving symptoms.

Step 1: Environmental and Behavioural Changes

Reduce screen time or use the 20-20-20 rule — every 20 minutes, look at something 20 feet away for 20 seconds. Increase blink frequency consciously. Use a humidifier in air-conditioned environments. Wear wraparound glasses in wind and dry air.

Step 2: Lid Hygiene and Warm Compresses

Warm compresses applied for 10 minutes daily soften meibomian secretions and improve gland expressibility. Lid massage after warming clears blocked glands. Lid scrubs with baby shampoo or commercially prepared wipes reduce bacterial load on the lid margin.

Consistency matters more than intensity. Daily lid hygiene over months produces measurable improvement in tear film quality.

Step 3: Lubricating Eye Drops

Not all lubricants are equivalent. Drops containing carboxymethylcellulose, sodium hyaluronate, or polyethylene glycol provide longer contact time. Preservative-free formulations are essential for patients using drops more than four times daily — preservatives accelerate the surface damage they are meant to relieve.

Gel formulations and ointments provide longer relief but blur vision temporarily and are best used at night.

Step 4: Omega-3 Fatty Acid Supplementation

Omega-3 supplements — particularly EPA and DHA from fish oil or re-esterified triglyceride formulations — improve meibomian secretion quality and reduce ocular surface inflammation. The DREAM study showed that high-dose omega-3 did not significantly outperform olive oil placebo, but clinical practice and other evidence support a role for supplementation in evaporative dry eye.

A daily dose of 2000 to 3000 mg EPA+DHA for at least three months is typically recommended.

Step 5: Anti-Inflammatory Therapy

When inflammation is driving symptoms, lubricants alone are insufficient. Cyclosporine eye drops (0.05% or 0.1%) reduce T-cell mediated inflammation on the ocular surface and restore goblet cell density over three to six months of use. They are not a quick fix — patients must be counselled on the time course.

Lifitegrast 5% is an integrin antagonist that blocks the LFA-1 to ICAM-1 interaction driving ocular surface inflammation. It offers symptom relief somewhat faster than cyclosporine.

Short-term topical corticosteroids are used to rapidly break the inflammatory cycle, particularly at disease onset or during flares. They are not for long-term use.

Step 6: Procedural Treatments

Intense Pulsed Light (IPL) therapy targets abnormal blood vessels on the lid margin that drive meibomian gland inflammation. It also applies heat that melts obstructed meibum. Multiple sessions spaced three to four weeks apart produce sustained improvement in many patients with moderate to severe MGD.

Thermal pulsation devices (LipiFlow) deliver controlled heat and pressure to the inner eyelid to express inspissated meibum. The effect can last six to twelve months and is repeatable.

Punctal plugs block the drainage of tears from the ocular surface. They are appropriate for aqueous deficient dry eye when lubrication alone is inadequate. Dissolvable collagen plugs are trialled before permanent silicone plugs are inserted.

TreatmentBest ForTime to Effect
Preservative-free lubricantsAll types, daily useImmediate symptom relief
Lid hygiene + warm compressesEvaporative / MGD4 to 8 weeks of daily use
Omega-3 supplementationEvaporative / MGD8 to 12 weeks
Cyclosporine dropsInflammatory DED3 to 6 months
Lifitegrast dropsInflammatory DED2 to 4 weeks for symptoms
IPL therapyModerate to severe MGDAfter 3 to 4 sessions
Punctal plugsAqueous deficient DEDDays to weeks

Monitoring Dry Eye Over Time

Dry eye is managed, not cured. Follow-up visits every three to six months allow the specialist to assess treatment response, adjust the regimen, and monitor for corneal surface deterioration.

Objective tests — TBUT, osmolarity, staining scores — are more reliable than symptoms alone. Patients often adapt to chronic discomfort and underreport severity. Imaging guides clinical decisions even when symptoms appear stable.

Meibomian gland dropout is irreversible. Preventing further loss is the priority once significant atrophy is identified.

Dry Eye and Systemic Disease

Dry eye is frequently a signal of systemic disease. Sjogren’s syndrome, rheumatoid arthritis, lupus, thyroid eye disease, and graft-versus-host disease all affect the ocular surface. Patients with unexplained severe dry eye — particularly younger women — should be evaluated for autoimmune conditions.

Conversely, patients already diagnosed with these conditions should have formal ocular surface assessments. Dry eye in this context needs co-management with the treating physician.

When to See a Glaucoma and Ocular Surface Specialist

Many patients with dry eye also have glaucoma or glaucoma suspect status. Glaucoma drops — particularly those with preservatives — are a significant cause of ocular surface disease. The benzalkonium chloride (BAK) in most preserved glaucoma drops is toxic to goblet cells and the corneal epithelium.

If you use glaucoma drops and have dry eye symptoms, your specialist needs to review both conditions together. Switching to preservative-free formulations or fixed-combination drops can reduce surface toxicity without compromising IOP control.

A specialist with expertise in both conditions can optimise your glaucoma management while actively protecting the ocular surface.

Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.

Frequently Asked Questions

Can dry eye disease be cured?

There is no permanent cure for most forms of dry eye disease. However, it can be very well controlled with the right treatment strategy. Many patients achieve significant symptom relief and stable ocular surface health with long-term management.

Are lubricating drops enough to treat dry eye?

For mild disease, lubricants provide adequate relief. For moderate to severe dry eye — or evaporative disease driven by meibomian gland dysfunction — drops manage symptoms but do not address the underlying cause. Lid hygiene, anti-inflammatory therapy, and sometimes procedural treatment are needed.

How do I know if my dry eye is getting worse?

Worsening symptoms, increased frequency of drop use, morning grittiness, light sensitivity, and fluctuating vision are all signs of progression. Objective worsening on TBUT, staining, or osmolarity testing confirms it. Do not wait for significant discomfort before seeking review.

Can diet help with dry eye?

Yes. Omega-3 fatty acids from oily fish, flaxseed, and walnuts support meibomian gland secretion quality. Adequate hydration matters. Foods high in omega-6 fatty acids and processed vegetable oils may worsen inflammation. A Mediterranean-style diet is broadly supportive of ocular surface health.

Is dry eye related to screen use?

Yes. Screen use reduces spontaneous blink rate from a normal 15 to 17 blinks per minute to as few as 3 to 5 blinks per minute. Reduced blinking causes tear film instability and accelerates evaporation. Deliberate blinking exercises and regular screen breaks are first-line recommendations for screen-related dry eye.

Can I wear contact lenses if I have dry eye?

Some patients with well-managed mild dry eye can wear contacts with modifications — daily disposable lenses, lubricating drops compatible with contact wear, and reduced wearing time. Patients with moderate to severe dry eye are advised to avoid contact lenses until surface health is restored. Scleral lenses are a specialist option for severe cases.

Does menopause cause dry eye?

Yes. Oestrogen and androgen deficiency after menopause reduces both aqueous and meibomian secretion. Dry eye prevalence in post-menopausal women is significantly higher than in age-matched men. Hormone replacement therapy has a complex relationship with dry eye — some studies show benefit, others do not. Ocular surface assessment after menopause is advisable.

Book a Dry Eye Assessment in Gurgaon

Dry eye responds best to early, structured management. A thorough ocular surface assessment — including meibography, osmolarity, and staining — identifies the cause and guides a treatment plan that works long-term.

If you are using lubricating drops daily and still struggling, the underlying mechanism has not yet been addressed. A specialist review changes that.

About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Access her work on PubmedGoogle ScholarResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read More

Basics of Dry Eye

Dry Eye Second Opinion

Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often?

Menopause and Dry Eye

Dry Eyes: Natural Remedies

Dry Eyes: Tips to Soothe Sore Eyes

Why Dry Eye Is Worse in Air Conditioning and on Flights

Why Vision Becomes Blurred After Reading or Screen Use

Screen Fatigue

Why Your Eyes Water Constantly

Omega-3 and Dry Eye

Why Are Your Dry Eye Drops Not Working

Autologous Serum Eye Drops for Severe Dry Eye

Glaucoma and Dry Eye

Why Vision Becomes Blurred After Reading or Screen Use

Many people notice an unusual pattern with their vision, and wonder why vision becomes blurred after reading or screen use….

Meibomian Gland Disease

Meibomian Gland Disease (MGD) is a common yet often underdiagnosed eye condition that can significantly impact your ocular comfort and vision. Understanding MGD, its causes, symptoms, and available treatments, is crucial for maintaining healthy eyes and improving your quality of life.